Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NASDAQ: NCNA) is a clinical-stage biopharmaceutical company focused on developing ProTide-based cancer therapies, and the NCNA news feed highlights the company’s ongoing clinical, regulatory, and corporate developments. NuCana reports that it is applying its proprietary ProTide technology to transform widely used nucleoside analog chemotherapy agents into new medicines designed to overcome key limitations of these drugs and generate higher concentrations of active anti-cancer metabolites in cancer cells.
News about NuCana frequently centers on its two lead product candidates, NUC-7738 and NUC-3373. Coverage includes updates from the NuTide:701 Phase 1/2 study of NUC-7738 in advanced solid tumors and in combination with pembrolizumab in patients with melanoma, including PD-1 inhibitor-resistant metastatic melanoma. Articles also report on data from the NuTide:303 Phase 1b/2 study of NUC-3373 in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer, as well as preclinical findings that explore immunogenic effects and synergy with PD-1 inhibitors.
Investors following NCNA news can expect announcements on clinical data presented at major oncology meetings, such as European Society for Medical Oncology congresses, publications in scientific journals and preprint servers, and updates on intellectual property, including composition-of-matter patents for NUC-7738. The news flow also covers financial results, capital-raising activities such as at-the-market offerings and warrant transactions, Nasdaq listing and ADS ratio changes, and leadership or board changes reported in Form 6-K filings.
This page aggregates these company-issued press releases and related disclosures so readers can monitor NuCana’s progress in oncology drug development, track milestones for NUC-7738 and NUC-3373, and review structural updates that may affect the NCNA stock listing and capital structure.
NuCana plc (NASDAQ: NCNA) reported Q3 financial results for 2022, showing a reduced net loss of £4.5 million, down from £8.0 million year-over-year. Cash reserves increased to £50.8 million, providing a runway through 2025. The company advances its ProTide therapeutics, with two Phase 2 studies initiated for NUC-3373 in colorectal cancer and solid tumors. Positive data were presented at major oncology meetings, enhancing confidence in NUC-3373 and NUC-7738's effectiveness. Key milestones are anticipated in Q4 2022 and the first half of 2023.
NuCana plc (NASDAQ: NCNA) will present at the Jefferies London Healthcare Conference on November 16, 2022, at 2:40 PM GMT. CEO Hugh Griffith and CFO Don Munoz will lead discussions and one-on-one meetings at the event held in London, UK. The presentation will be available for live webcast and later replay on the company’s website under ‘Events & Presentations’. NuCana focuses on enhancing cancer treatment through its ProTide technology, with a pipeline including NUC-3373 and NUC-7738.
NuCana plc (NASDAQ: NCNA) announced promising non-clinical results for NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting. Data suggest NUC-3373, a potent thymidylate synthase (TS) inhibitor, induces significant DNA damage in various non-small cell lung cancer (NSCLC) cell lines and increases immunogenic activity. The company has initiated the NuTide:303 study, evaluating NUC-3373 in combination with pembrolizumab or docetaxel for patients with advanced solid tumors. Results highlight NUC-3373's potential as a significant treatment option for NSCLC, reinforcing the company's strategic focus on enhancing chemotherapy efficacy.
NuCana plc (NASDAQ: NCNA) presented promising results for NUC-7738 at the ESMO Annual Meeting, indicating significant anti-tumor activity in advanced solid tumors, particularly melanoma. The Phase 1 data of the NuTide:701 study showed that many patients remained on treatment for extended periods, with low rates of treatment-related adverse events. NUC-7738, which aims to enhance the anti-cancer effects of 3'-deoxyadenosine, is set to proceed to Phase 2 trials, including a combination with pembrolizumab. The favorable safety profile and potential efficacy mark a significant step forward for NuCana's cancer treatment pipeline.
NuCana plc (NASDAQ: NCNA) announced positive results from its NuTide:302 study on NUC-3373, demonstrating good anti-tumor activity and safety in heavily pre-treated colorectal cancer patients. Data presented at the ESMO Annual Meeting showed that both NUFIRI and NUFOX regimens yielded promising progression-free survival rates, with 80% disease control for NUFOX. A new randomized study, NuTide:323, has been initiated, comparing NUFIRI with FOLFIRI. NUC-3373 aims to improve on 5-FU's limitations, potentially transforming treatment for colorectal cancer.
NuCana plc (NASDAQ: NCNA) announced two key presentations at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris from September 9-13. The first presentation features NUC-3373, a novel treatment for advanced colorectal cancer, on September 11, while the second showcases NUC-7738, a new anti-cancer agent, on September 12. NUC-3373 aims to enhance the efficacy and safety of existing therapies, while NUC-7738 targets solid tumors. Both products are part of NuCana's ongoing commitment to improving cancer treatment outcomes through innovative ProTide technology.
NuCana plc (NASDAQ: NCNA) will engage in one-on-one meetings at Citi's 17th Annual BioPharma Conference, taking place from September 6-8, 2022, in Boston, MA. The company focuses on enhancing cancer treatment via its ProTide technology, improving the efficacy and safety of conventional chemotherapy agents. Key product candidates include NUC-3373, currently in multiple Phase 1b/2 studies for advanced colorectal cancer, and NUC-7738, in Phase 2 evaluation for advanced solid tumors. These efforts aim to address significant treatment limitations.
NuCana plc (NASDAQ: NCNA) reported financial results for Q2 2022, showing a net loss of £3.9 million, significantly improved from £9.1 million in Q2 2021. Cash reserves decreased to £46.5 million from £52.6 million in Q1 2022. The company announced multiple clinical trials, including NuTide:323 and NuTide:303, aimed at enhancing cancer treatment options. Additionally, NuCana regained compliance with Nasdaq listing requirements. There is an anticipated cash runway into 2025, supporting ongoing clinical developments and promising data updates expected in the near future.
NuCana plc (NASDAQ: NCNA) announced it has regained compliance with the Nasdaq Minimum Bid Price Requirement after a period of non-compliance. The company received a notification confirming that its American Depositary Shares (ADSs) maintained a closing bid price of $1.00 or more for 10 consecutive business days from July 13 to July 26, 2022. This follows previous notification on June 3, 2022, regarding falling below the minimum required price. NuCana focuses on improving cancer treatment outcomes using its innovative ProTide technology, with ongoing clinical trials for its product candidates.
NuCana (NASDAQ: NCNA) announced a significant legal victory on July 7, 2022, when the Regional Court of Dusseldorf ruled that Gilead Sciences violated NuCana’s European Patent 2955190 regarding their products Sovaldi®, Harvoni®, Vosevi®, and Epclusa® in Germany. The court's decision comes after Gilead’s failed attempts to invalidate the patent. Following the judgment, Gilead may appeal, and ongoing UK litigation regarding the patent remains unresolved. NuCana continues to develop innovative cancer treatments utilizing its proprietary ProTide technology.